Fig. 3

Fig. 3

waif1a Inhibits wnt8 Function in Mesoderm and Neuroectoderm Patterning (A) Reduction of the forebrain marker otx2 and expansion of the posterior neural marker hoxb1b at the 100% epiboly stage in embryos injected with 10 ng waif1a MO1 or MO2 (23 of 28 embryos MO1, 21 of 24 MO2). (B) Changes in size of the telencephalic foxg1a expression domain at the one somite stage (bracket) in embryos injected with 2 ng each of wnt8.1 and wnt8.2 MOs (20 of 21 embryos), 160 pg waif1a RNA (36 of 36), 0.4 pg wnt8 RNA (22 of 26), and 4 ng of waif1a MO1 (16 of 25) without or with 2 pg axin1 RNA (17 of 23). (C) Changes in the size of the dorsal gsc expression domain at the 50% epiboly stage (arrowheads) in embryos injected with 2 ng each of wnt8.1 and wnt8.2 MOs (41 of 42 embryos), 150 pg waif1a RNA (35 of 44), and 10 ng waif1a MO1 (20 of 21 embryos), relative to embryos injected with equimolar amounts of luciferase control RNA plus control MO and in hsp70l:Wnt8-GFP transgenic embryos heat shocked at 30% epiboly (46 of 46 embryos). (D) Head regions with eyes (arrows) and midbrain-hindbrain boundary (arrowheads) indicated at 24 hpf of embryos injected with 10 ng waif1a MO1 and 0.2 ng standard control MO, or 0.2 ng tcf3a MO plus 10 ng control MO. (E) Quantification of the tcf3a and waif1a knockdown synergy. Embryos were classified using the criteria introduced in Figure 2A, ^***p < 0.001, chi-square test. See also Figure S3.